Covid 19 Research using Clinical Trials (Home Page)
HP:0100806: SepsisHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1410 | Toraymyxin PMX-20R (PMX Cartridge) Wiki | 0.71 |
| drug1552 | draw blood Wiki | 0.71 |
Correlated MeSH Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018805 | Sepsis NIH | 0.82 |
| D012772 | Shock, Septic NIH | 0.71 |
| D019446 | Endotoxemia NIH | 0.71 |
| D012769 | Shock, NIH | 0.35 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.03 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 2 clinical trials
Clinical Trials
1 Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19
Prospective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock
NCT04352985 Septic Shock Endotoxemia COVID Corona Virus Infection Sepsis, Severe Device: Toraymyxin PMX-20R (PMX Cartridge) MeSH:Shock, Septic Endotoxemia Sepsis Coronavirus Infections Severe Acute Respiratory Syndrome Shock
HPO:Sepsis
2 SQuISH-COVID: A Pilot Study
This is a single-site prospective study to evaluate the diagnostic performance of the investigational SeptiScan System for patients presenting to the Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases.
NCT04372472 Sepsis COVID-19 MeSH:Sepsis
HPO:Sepsis
Primary Outcomes
Description: The SeptiScan System is an investigational microfluidic assay that measures the biophysical properties of human leukocytes as an aid, in conjunction with other clinical assessments, to detect life-threatening organ dysfunction caused by a dysregulated host immune response to infection. The SeptiScan System score is presented in three Interpretation Bands of low, intermediate, and high probability of disease. Remnant blood samples will be obtained from subjects in Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases. The blood samples will be analyzed using the SeptiScan System.
Measure: To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection. Time: Day of enrollment through Day 5
HPO Nodes
HP:0100806: Sepsis
Genes 76
EDN3 G6PC3 IL2RG CXCR4 PIK3R1 HYOU1 ATP7A IL2RG SEMA3C CD79A MMUT MYH11 TGM1 AK2 CYBB CYP4F22 ALOXE3 COG4 GDNF DCLRE1C BLNK CTNNB1 ELANE RET RMRP TCF3 RAG1 PGM3 ITGB4 MYLK ALOX12B VPS33A EDNRB TFRC LRRC8A CTCF ABCA12 ACTG2 SERAC1 CHD7 FOXP3 ADA NCF4 SDR9C7 PLEC ECE1 HLA-B LIPN WAS SEMA3D NFKB2 LMOD1 AK2 WIPF1 NRTN SULT2B1 CD79B IGHM IL7R GALT NCF1 CYBC1 SAMD9 CYBA IGLL1 IKZF1 IL7R RAG2 FERMT3 APC MNX1 BTK LIG4 RAG1 NIPAL4 NCF2
Primary Outcomes
Description: The SeptiScan System is an investigational microfluidic assay that measures the biophysical properties of human leukocytes as an aid, in conjunction with other clinical assessments, to detect life-threatening organ dysfunction caused by a dysregulated host immune response to infection. The SeptiScan System score is presented in three Interpretation Bands of low, intermediate, and high probability of disease. Remnant blood samples will be obtained from subjects in Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases. The blood samples will be analyzed using the SeptiScan System.
Measure: To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection. Time: Day of enrollment through Day 5